Serum Asymmetric Dimethyl Arginine Level is Associated with the Pain Intensity in Primary Dysmenorrhea

Abstract

Background: Aim of this study is the investigation of the association between Serum Asymmetric Dimethyl Arginine (ADMA) levels and menstrual pain intensity as assessed by Visual Analogue Scale in primary dysmenorrhea patients.

Methods: Eighty-nine young women with primary dysmenorrhea (PD) were selected as study group. PD pain was graded using Visual Analogue Scale (VAS), as mild, moderate and severe. Serum ADMA levels was measured in all subjects.

Results: Mean age of study population was 21.08±2.21 and mean VAS score was 5.9101±2.18. Serum ADMA levels were 35.2(24) in mild, 54.0(28.7) in moderate and 56.5(32.8) in severe pain groups, (P= 0.029 and P=0.001, respectively). Mean ADMA levels difference were -18.8, p=0.046 in mild to moderate; -2.52, p=0. 945 in moderate to severe and 21.32 p=0.048 in severe to mild pain groups.  

Conclusion: Menstrual pain intensity is correlated with the serum ADMA levels as assessed by VAS pain score in PD patients

Keywords

• Asymmetric Dimethyl Arginine,Pain Intensity,Primary Dysmenorrhea

References

1. Akdemir N, Cinemre H, Bilir C, Akin O, Akdemir R. Increased serum asymmetric dimethyl arginine levels in primary dysmenorrhea. Gynecol Obstet Invest. 2010; 69(3): 153-6.
2. 2. Lefebvre G, Pinsonneault O, Antao V, Black A, Burnett M, Feldman K, et.al. Primary dysmenorrhea consensus guideline. J Obstet Gynaecol Can. 2005; 27(12): 1117-46.
3. 3. Iacovides S, Avidon I, Baker FC. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update. 2015; 21(6): 762-78.
4. 4. Haman JO. Pain threshold in dysmenorrhea. Am J Obstet Gynecol 1944; 47:686–69
5. 5. Savvidou MD, Hingorani AD, Tsikas D, Frölich JC, Vallance P, Nicolaides KH. Endothelial dysfunction and raised plasma concentrations of asymmetric dimethylarginine in pregnant women who subsequently develop pre-eclampsia. Lancet. 2003; 361(9368): 1511-7.
6. 6. Charitidou C, Farmakiotis D, Zournatzi V, Pidonia I, Pegiou T, Karamanis N, et.al. The administration of estrogens, combined with anti-androgens, has beneficial effects on the hormonal features and asymmetric dimethyl-arginine levels, in women with the polycystic ovary syndrome. Atherosclerosis. 2008;196(2):958-65.
7. 7. Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986; 27(1): 117-26.
8. 8. Carlsson AM. Assessment of chronic pain. I. Aspects of the reliability and validity of the visual analogue scale. Pain 1983; 16:87-101.

9. 9. Paice J, Cohen F. Validity of a verbally administered numeric rating scale to measure cancer pain intensity. Cancer Nurs 1997; 20:88-93.
10. 10. Jones KR, Fink R, Hutt E, Vojir C, Pepper GA, Scott-Cawiezell J, Mellis BK.. Measuring pain intensity in nursing home residents. J Pain Symptom Manage. 2005; 30(6): 519-27.
11. . Blackwell S. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine. Ann Clin Biochem. 2010;47(Pt 1):17-28.
12. 12. Akdemir N, Cinemre FB, Bostancı MS, Cinemre H, Ünal O, Ozden S, et.al. The correlation of serum asymmetric dimethylarginine and anti-Müllerian hormone in primary dysmenorrhea. Kaohsiung J Med Sci. 2016;32(8):414-9.
13. 13. Akdemir N, Akhin O. Increased serum asymmetric dimethylarginine levels in hyperemesis gravidarum. Arch Gynecol Obstet. 2012;285(2):339-42.
14. 14. Sari I, Kebapcilar L, Alacacioglu A, Bilgir O, Yildiz Y, Taylan A, et.al. Increased levels of asymmetric dimethylarginine (ADMA) in patients with ankylosing spondylitis. Intern Med. 2009;48(16):1363-8.
15. 15. Holden DP, Fickling SA, Whitley GS, Nussey SS. Plasma concentrations of asymmetric dimethylarginine, a natural inhibitor of nitric oxide synthase, in normal pregnancy and preeclampsia. Am J Obstet Gynecol. 1998;178(3):551-6.
16. 16. Kielstein H, Suntharalingam M, Perthel R, Song R, Schneider SM,
17. Martens-Lobenhoffer J, et.al. Role of the endogenous nitric oxide inhibitor asymmetric dimethylarginine (ADMA) and brain-derived neurotrophic factor (BDNF) in depression and behavioural changes: clinical and preclinical data in chronic kidney disease. Nephrol Dial Transplant. 2015;30(10):1699-705.
18. 17. Karakurt F, Carlioglu A, Kaygusuz I, Gumus II, Uz B, Akdeniz D. Effect of ethinyl estradiol-cyproterone acetate treatment on asymmetric dimethyl-arginine levels in women with polycystic ovary syndrome. Arch Gynecol Obstet. 2014; 289(1): 135-40.
19. 18. Pamuk BO, Torun AN, Kulaksizoglu M, Ertugrul D, Ciftci O, Kulaksizoglu S, et.al. Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. Fertil Steril. 2010; 93(4): 1227-33.
20. .
21. Pamuk BO, Torun AN, Kulaksizoglu M, Ertugrul D, Ciftci O, Kulaksizoglu S, et.al. Asymmetric dimethylarginine levels and carotid intima-media thickness in obese patients with polycystic ovary syndrome and their relationship to metabolic parameters. Fertil Steril. 2010; 93(4): 1227-33.
22. 19. Valtonen P, Punnonen K, Saarelainen H, Heiskanen N, Raitakari OT, Juonala M, et.al. ADMA concentration changes across the menstrual cycle and during oral contraceptive use: the Cardiovascular Risk in Young Finns Study. Eur J Endocrinol. 2010;162(2):259-65.
23. 20. Holden DP, Cartwright JE, Nussey SS, Whitley GS. Estrogen stimulates dimethylarginine dimethylaminohydrolase activity and the metabolism of asymmetric dimethylarginine. Circulation. 2003;108(13):1575-80.
24. 21. Verhoeven MO, Hemelaar M, van der Mooren MJ, Kenemans P, Teerlink T. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy ostmenopausal women: a randomized, placebo-controlled study. J Intern Med. 2006;259(2):199-208.
25. 22. Cevik D, Unay O, Durmusoglu F, Yurdun T, Bilsel AS. Plasma markers of NO synthase activity in women after ovarian hyperstimulation: influence of estradiol on ADMA. Vasc Med. 2006;11(1):7-12.
26. 23. Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P. Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. PLoS Med. 2005;2(10):e264.
27. 24. DʼMello R, Sand CA, Pezet S, Leiper JM, Gaurilcikaite E, McMahon SB, et.al. Dimethylarginine dimethylaminohydrolase 1 is involved in spinal nociceptive plasticity. Pain. 2015; 156(10): 2052-60.
28. 25. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1988;336:385-8.
29. 26. Garthwaite J, Garthwaite G, Palmer RM, Moncada S. NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur J Pharmacol 1989;172:413-16.
30. Guan Y, Yaster M, Raja SN, Tao YX. Genetic knockout and pharmacologic inhibition of neuronal nitric oxide synthase attenuate nerve injury-induced mechanical hypersensitivity in mice. Mol Pain 2007;3:29.
31. 28. Haley JE, Dickenson AH, Schachter M. Electrophysiological evidence for a role of nitric oxide in prolonged chemical nociception in the rat. Neuropharmacology 1992;31:251-8.
32. 29. Herdegen T, Rüdiger S, Mayer B, Bravo R, Zimmermann M. Expression of nitric oxide synthase and colocalisation with Jun, Fos and Krox transcription factors in spinal cord neurons following noxious stimulation of the rat hindpaw. Brain Res Mol Brain Res 1994;22:245-58.
33. 30. Kielstein A, Tsikas D, Galloway GP, Mendelson JE. Asymmetric dimethylarginine (ADMA)–a modulator of nociception in opiate tolerance and addiction? Nitric Oxide 2007;17:55-9.
34. 31. Kitto KF, Haley JE, Wilcox GL. Involvement of nitric oxide in spinally mediated hyperalgesia in the mouse. Neurosci Lett 1992;148:1-5.